ADIL vs. YMTX, LIXT, OGEN, KTRA, ENVB, HILS, XBIO, KA, HOTH, and AIMD
Should you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Yumanity Therapeutics (YMTX), Lixte Biotechnology (LIXT), Oragenics (OGEN), Kintara Therapeutics (KTRA), Enveric Biosciences (ENVB), Hillstream BioPharma (HILS), Xenetic Biosciences (XBIO), Kineta (KA), Hoth Therapeutics (HOTH), and Ainos (AIMD). These companies are all part of the "pharmaceutical preparations" industry.
Yumanity Therapeutics (NASDAQ:YMTX) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.
Adial Pharmaceuticals has lower revenue, but higher earnings than Yumanity Therapeutics. Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Yumanity Therapeutics, indicating that it is currently the more affordable of the two stocks.
Adial Pharmaceuticals received 94 more outperform votes than Yumanity Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Yumanity Therapeutics an outperform vote while only 58.06% of users gave Adial Pharmaceuticals an outperform vote.
25.1% of Yumanity Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 12.5% of Yumanity Therapeutics shares are owned by insiders. Comparatively, 14.5% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Yumanity Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.
In the previous week, Adial Pharmaceuticals had 4 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 0 mentions for Yumanity Therapeutics. Yumanity Therapeutics' average media sentiment score of 1.43 beat Adial Pharmaceuticals' score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.
Adial Pharmaceuticals has a net margin of 0.00% compared to Adial Pharmaceuticals' net margin of -660.61%. Yumanity Therapeutics' return on equity of -250.52% beat Adial Pharmaceuticals' return on equity.
Summary
Adial Pharmaceuticals beats Yumanity Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Adial Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adial Pharmaceuticals Competitors List
Related Companies and Tools
